Cellectar Biosciences, Inc.

NetDania - New 12 months Low: Cellectar Biosciences, Inc.

22 May 2018 09:56:19 By NetDania Notify

NetDania - New 12 months Low: Cellectar Biosciences, Inc.

02 Apr 2018 10:28:03 By NetDania Notify

NetDania - New 12 months Low: Cellectar Biosciences, Inc.

08 Jan 2018 10:54:42 By NetDania Notify

NetDania - New 12 months Low: Cellectar Biosciences, Inc.

14 Dec 2017 13:17:31 By NetDania Notify

Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma

22 Feb 2017 08:31:14 By Nasdaq GlobeNewswire

UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

13 Feb 2017 07:00:16 By Nasdaq GlobeNewswire

Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

07 Feb 2017 08:31:07 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform

31 Jan 2017 08:30:43 By Nasdaq GlobeNewswire

Cellectar Biosciences to Present at NobleCon13

26 Jan 2017 08:30:49 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors

24 Jan 2017 08:30:30 By Nasdaq GlobeNewswire

Cellectar Biosciences to Present at the 9th Annual Biotech Showcase

05 Jan 2017 08:30:32 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs

20 Dec 2016 08:30:38 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types

14 Dec 2016 08:30:34 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035

12 Dec 2016 08:30:59 By Nasdaq GlobeNewswire

Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology  

06 Dec 2016 08:30:26 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies

01 Dec 2016 08:02:50 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option

29 Nov 2016 18:40:29 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production

28 Nov 2016 08:00:54 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering

23 Nov 2016 08:30:29 By Nasdaq GlobeNewswire

Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors

17 Nov 2016 08:00:44 By Nasdaq GlobeNewswire